La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Accounts Receivable : $5.93 Mil (As of Jun. 2022)

View and export this data going back to 1994. Start your Free Trial

What is La Jolla Pharmaceutical Co Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. La Jolla Pharmaceutical Co's accounts receivables for the quarter that ended in Jun. 2022 was $5.93 Mil.

Accounts receivable can be measured by Days Sales Outstanding. La Jolla Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Jun. 2022 was 51.30.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. La Jolla Pharmaceutical Co's Net-Net Working Capital per share for the quarter that ended in Jun. 2022 was $-4.63.

La Jolla Pharmaceutical Co Accounts Receivable Historical Data

The historical data trend for La Jolla Pharmaceutical Co's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

La Jolla Pharmaceutical Co Accounts Receivable Chart

La Jolla Pharmaceutical Co Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Accounts Receivable

Get a 7-Day Free Trial

1.38

2.96

5.83

8.61

La Jolla Pharmaceutical Co Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Accounts Receivable	Get a 7-Day Free Trial															8.60	8.79	8.61	5.73	5.93

La Jolla Pharmaceutical Co Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

La Jolla Pharmaceutical Co Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

La Jolla Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Jun. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	5.927	/	10.543	*	91
=	51.30

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), La Jolla Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

La Jolla Pharmaceutical Co's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2022 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(48.661	+	0.75 * 5.927	+	0.5 * 8.299	-	168.834
-	3.907	-	0)	/	24.9505
=	-4.63

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

La Jolla Pharmaceutical Co Accounts Receivable Related Terms

Thank you for viewing the detailed overview of La Jolla Pharmaceutical Co's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » La Jolla Pharmaceutical Co (NAS:LJPC) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Jones Road, Suite 400, Waltham, MA, USA, 02451

Website

http://www.ljpc.com

La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.

Executives

Larry G. Edwards	director, officer: Chief Executive Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David A Ramsay	director	HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Michael S Hearne	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Robert Rosen	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Kevin C Tang	director, 10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Darryl Wellinghoff	officer: Chief Commercial Officer	4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Lakhmir S Chawla	officer: Chief Medical Officer	1960 KIRBY ROAD, MCLEAN VA 22101
Jennifer Carver	officer: Sr. Vice President, Operations	725 NEWPORT STREET, DENVER CO 80220
James Rolke	officer: Chief Scientific Officer	10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
George F Tidmarsh	director, officer: President, CEO & Secretary